Parent :
Type :
Core Business :
Develops, manufactures and markets a vaccine to eradicate fish diseases, particularly for the KHV viral disease in the Common Carp and Koi fish.
Main Markets :
Overview :
KOVAX LTD. was established in 2003 in order to develop, manufacture and market a vaccine to eradicate fish diseases.
The company has Vaccine-manufacturing capabilities as well as a high technology R&D department.
The KOVAX team is composed of talented individuals with complied qualifications, each successful in substantial fields. Essential for the project success: Science frontier, outstanding business development and project management success.
KOVAX has acquired the patent for the KHV vaccine (For KOI and Common Carp ) and the immune-based diagnostic kit from the Hebrew University and the Israeli Ministry of Agriculture. The KHV vaccine was developed by Professor Moshe Kotler.
KOVAX is the only company in the world that produces and markets an efficient and safe vaccine against KHV disease.
Starting 2006 KOVAX R&D department is focusing on development - "Novel vaccine methodology".